A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)-Reference-Cited by-同舟云学术

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

Published:2013-11-05 Issue:1 Volume:73 Page:181-189
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Molina Ana M.,Hutson Thomas E.,Larkin James,Gold Anne M.,Wood Karen,Carter Dave,Motzer Robert,Michaelson M. Dror

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-013-2339-y/fulltext.html

Reference34 articles.

1. Rini BI, Atkins MB (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10:992–1000. doi: 10.1016/S1470-2045(09)70240-2

2. Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55:851–863. doi: 10.1016/j.eururo.2009.01.003

3. Hutson TE (2011) Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(suppl 2):14–22. doi: 10.1634/theoncologist.2011-S2-14

4. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A, RECORD-1 Study Group (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265. doi: 10.1002/cncr.25219

5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer, Version 1. (2013). http://file3.baitianshi.com/upload/res/201212/c29/9f/5c8d5.pdf . Accessed 20 Feb 2013

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-06-26

2. The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice;Medical alphabet;2024-05-09

3. Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients;Therapeutic Advances in Urology;2024-01

4. Deep learning-assisted survival prognosis in renal cancer: A CT scan-based personalized approach;Heliyon;2024-01

5. Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery;Frontiers in Oncology;2023-12-13